IL1B and myocardial infarction: In patients with prior myocardial infarction and elevated hs-CRP, canakinumab, a monoclonal antibody inhibiting IL-1β, administered every three months, significantly reduced major adverse cardiovascular events compared to placebo without materially altering LDL-C levels [31].